Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Related Articles
Fruquintinib Combo Exhibits Manageable Safety Profile in Pretreated mCRC
Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.
Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.
Addressing Unmet Needs in Patients Undergoing Treatment for Rare Lymphomas
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC
Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.
ctDNA May Help to Predict Early Recurrence in Stage III Melanoma
ctDNA levels may help to predict early recurrence for patients with stage III melanoma before adjuvant therapy and during follow-up.
Cancer Mortality Shows Long-Term Declines Despite COVID-19 Pandemic
An annual report on the status of cancer showed that, from 2018 to 2022, the cancer death rate fell for every race and ethnicity.
Medical Education May Improve Care for Breast Cancer Minority Populations
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress
Patients with a cancer signal detected via multicancer early detection test demonstrated similar results to those who did not in the PATHFINDER cohort study.
Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL
A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.
UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications
Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.